South Dakota Investment Council Coherus Bio Sciences, Inc. Transaction History

South Dakota Investment Council

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Aug 11, 2022	SELL	$5.86 - $13.23 $56,537 - $127,643	-9,648 Closed	0 $0
Q1 2022 May 10, 2022	SELL	$10.92 - $16.41 $1.05 Million - $1.58 Million	-96,473 Reduced 90.91%	9,648 $125,000
Q3 2021 Nov 09, 2021	SELL	$12.68 - $17.79 $751,924 - $1.05 Million	-59,300 Reduced 35.85%	106,121 $1.71 Million
Q2 2021 Aug 11, 2021	BUY	$12.95 - $15.41 $1.46 Million - $1.74 Million	112,890 Added 214.9%	165,421 $2.29 Million
Q1 2021 May 13, 2021	BUY	$14.42 - $21.39 $492,558 - $730,639	34,158 Added 185.91%	52,531 $767,000
Q3 2020 Nov 06, 2020	BUY	$17.41 - $19.89 $128,363 - $146,648	7,373 Added 67.03%	18,373 $337,000
Q2 2020 Aug 13, 2020	BUY	$14.43 - $19.16 $158,730 - $210,760	11,000 New	11,000 $196,000

135

77.9M

40.7K

50.1K

Ticker CHRS
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 77,724,600
Market Cap $122M
Description
Coherus BioSciences, Inc., a biopharmaceutical company, focuses on the biosimilar and immuno-oncology market primarily in the United States. The company markets UDENYCA, a biosimilar to Neulasta, a long-acting granulocyte stimulating colony factor in the United States. Its pipeline products include biosimilars of Humira, Avastin, and Lucentis. T...

Get notified when there are updates to the investment portfolio of South Dakota Investment Council, based on Form 13F filings with the SEC.

Stay updated on South Dakota Investment Council with notifications on news.